According to the latest information published by Credence Research, Inc. “Tamoxifen: industry Growth, Future Prospects and Competitive Analysis, 2016-2022,” the tamoxifen industry was valued at USD 675.7 Mn in 2015, and is expected to reach USD 683.6 Mn by 2022, expanding at a CAGR of 0.07% from 2016 to 2022.
Tamoxifen is the oldest and among the most prescribed selective estrogen receptor modulator for breast cancer treatment and management. Tamoxifen is approved for early stage, hormone receptor positive breast cancer in men and women, after surgery or chemotherapy to reduce recurrence risk, and for management of advanced stage or metastatic hormone-receptor positive breast cancer. Women at high risk of developing breast cancer also use Tamoxifen. Tamoxifen is at the maturity stage of product life cycle and is anticipated to experience decline in industry growth in the light of introduction of advanced breast cancer management drugs.
Browse the full report Tamoxifen: Market Growth, Future Prospects and Competitive Analysis, 2016-2022 report at http://www.credenceresearch.com/report/tamoxifen-market
This information analyzes the geographical distribution of tamoxifen industry in North America, Europe, Asia-Pacific and Rest of the World industrys. Currently, North America is the largest industry for tamoxifen drugs and it is anticipated that the lead of this region will continue through 2022. Large pool of breast cancer patients, high awareness for breast cancer screening and prevention, well-structured reimbursement scenario and large pool of breast cancer patients. Asia-Pacific and Rest of the World industrys will experience the fastest CAGR during 2016-2022. Improving awareness in Middle East and Africa, high incidence of late stage breast cancer in these regions and rapid development of healthcare infrastructure are the prime drivers of Rest of the World industry.
Free sample : http://www.credenceresearch.com/sample-request/57902
Proven long-term efficiency of hormone therapy for management and control of breast cancer across various stages of treatment, in geriatric patients that cannot opt for surgery, and late-stage and recurrent breast cancer, and widespread use of tamoxifen as adjuvant therapy are the prime factors driving the demand for tamoxifen. Growth of tamoxifen-resistant cancer and growing awareness about the drug inducing endometrial cancer may restrain the industry growth. Growing application of tamoxifen in treatment of conditions such as McCune-Albright syndrome, infertility, gynecomastia, bipolar disorder, angiogenesis and Riedel’s thyroiditis, and its use in research studies involving gene expression serve as future avenues for the growth of this industry.
The global tamoxifen industry is moderately competitive with AstraZaneca, Teva Pharmaceutical Industries, Allergan, Mylan, Apotex and Midatech the known players. Anticipated merger of Teva with Allergan is expected to bring a shift in industry competition.
Credence Research is a worldwide industry research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Name: Chris Smith (Global Sales Manager)
Address: 105 N 1st ST #429, SAN JOSE, CA 95103 US